Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UPDATED March 7th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Trade Free for 60 Days and Get up to $600 when you open
Thx clay
OWCP live on the Radio Now
Jeff Friedland
http://www.blogtalkradio.com/stockradioonweed/2017/03/07/potstockradio-with-jeff-friedland-of-owc-pharma-and-tom-quigley-of-the-gluu
UPDATED March 6th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Trade Free for 60 Days and Get up to $600 when you open an E*TRADE Account!Advertisement
$OWCP - Listen to @OWCPharma @jeff_friedland TONIGHT ON @potstockradio 8PM EST
OWCP
#medicalmarijuana
#Marijuanastocks
#Marijuana
https://t.co/ica1S3D5BA
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
UPDATED March 3rd $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Trade from a
OWCP Related The latest in cannabis legalization including laws and policies, legislators’ views, election coverage, and more.
POLITICS
GW Pharma Responds: ‘Not Creating a Monopoly
https://www.leafly.com/news/politics/gw-pharma-responds-not-creating-monopoly
British drug manufacturer GW Pharma and its American subsidiary, Greenwich BioSciences, have responded to Leafly’s report last week about the company’s attempts to move proprietary cannabidiol (CBD) bills through at least two state legislatures.
GW/Greenwich says it is not opposing medical marijuana or CBD access.
That report noted that the company’s lobbyists were moving in anticipation of the FDA’s expected approval of Epidiolex, a CBD-based drug that’s currently in Phase III trials. GW/Greenwich is pushing bills through legislatures in South Dakota and Nebraska, where all forms of cannabis medicine remain illegal. The bills would specifically make only FDA-approved forms of CBD legal under state law.
As Leafly reported, the effect of such a law would be to give GW/Greenwich a virtual monopoly on legal CBD sales—at least temporarily. The original story also noted that the company has recently hired local political lobbyists in at least nine states.
RELATED STORY
Leafly Exclusive: GW Pharma is Moving CBD Bills on the Down Low
Steven Schultz, director of investor relations for GW/Greenwich, issued a response to the story to Alan Brochstein at New Cannabis Ventures. Schultz said he believed the story contained “significant factual errors,” although he did not offer evidence of error.
Here is the company’s statement to Brochstein in full:
GW expects to submit a NDA for Epidiolex in mid-2017 and wishes to ensure that, subject to FDA approval, Epidiolex can be made available to patients in as timely a manner as possible. One of the necessary steps to achieve this goal includes being proactive at the state level so that, once Epidiolex is approved by FDA and rescheduled by DEA, patients will be able to have access to the product in their states. This two-step process, both the DEA and local state rescheduling, is required to achieve full rescheduling and make our medicine available to appropriate patients with a doctor’s prescription.
It is important to stress that none of GW’s work involves opposing “medical marijuana” or “CBD access.” GW’s sole focus is on creating a pathway for our medicine, once approved by FDA. State and federal rescheduling of an FDA-approved product comprised of CBD will have no impact on existing (or future) state laws that allow the medical use of marijuana or of non-FDA approved CBD products.
Greenwich Biosciences/GW is not creating a monopoly. Rather, we are blazing a trail for any other CBD prescription medications that may follow since these regulations would not be specific to GW. In fact, it is likely new companies may be encouraged to enter the field of cannabinoid research, leading to a greater number of cannabinoid treatment options for patients, not fewer.
Unfortunately, the Leafly article does not mention the fact that GW is currently providing Epidiolex without cost to over 1,200 patients through compassionate use programs. GW’s goal is to provide an additional CBD option that meets the definition of, and has the hallmarks of, a modern medicine.
RELATED STORY
CBD vs. THC: Why Is CBD Not Psychoactive?
In a separate response to Leafly this afternoon, Schultz wrote that “it is not generally understood that rescheduling involves state rescheduling along with DEA rescheduling to enable FDA approved medicines that are Schedule 1 to be made available to patients.” Schultz added that GW/Greenwich remains “focused on this task, and understand what it takes at the state level–hence the local representatives.”
It may not be GW/Greenwich’s intention to create a monopoly on CBD products. Our original story noted that the proposed legislation “would effectively give GW/Greenwich a temporary monopoly on legal CBD products in South Dakota and Nebraska.” We stand by that statement. The company’s proprietary drug, Epidiolex, is the only CBD-based pharmaceutical nearing FDA approval. Hundreds of CBD oil manufacturers exist in medical marijuana states around the country, but the proposed legislation would make Epidiolex the one and only CBD drug legally available to epilepsy patients in states affected by the proposed bills, at least until another CBD-based drug receives FDA approval.
Whether intended or not, that is effectively a temporary monopoly.
The company has recently hired local political lobbyists in at least 22 states.
It’s true that GW/Greenwich has not publicly opposed the spread of medical cannabis legalization laws. Neither has it worked with local medical marijuana advocates, who have struggled for years to gain legal access to medical cannabis. Some of those advocates now worry that the GW/Greenwich legislation may undermine their own legalization efforts while limiting patients to a single CBD source.
National cannabis advocacy groups are somewhat divided on the issue. Beth Collins, director of government relations for Americans for Safe Access, told Leafly that her group is “not opposed to these bills as long as they don’t derail other efforts for full-plant legislation.” Collins noted that “there have been many instances where those with intractable epilepsy and other conditions have not responded well to Epidiolex, but have done very well on natural, less purified CBD extracts, such as Haleigh’s Hope or Charlotte’s Web.”
Those same concerns have led local leaders of Students for Sensible Drug Policy to oppose the bill in Nebraska. NORML Deputy Director Paul Armentano told Leafly on Wednesday that his group is discouraging support of the South Dakota bill. The clause that legalizes only FDA-approved forms of CBD, Armentano said, “essentially guts the bill.”
GW’s donation of Epidiolex to more than 1,200 patients is a truly commendable gesture. At the same time, it has no bearing on the company’s political push in American statehouses.
In our report last week, Leafly reported that GW/Greenwich had retained the services of political lobbyists in nine states. That portion of the story was, in fact, incorrect. Upon review of more recently filed state lobbying disclosure documents, we found that the company actually has contracted with lobbyists in at least 22 states for the 2017 legislative season.
RELATED STORY
How GW Pharma Could Use U.S. Patents to Shape the Future of Medical Cannabis
https://www.leafly.com/news/politics/how-gw-pharma-could-use-us-patents-to-shape-the-future-of-medical
UPDATED March 2nd $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
UPDATED March 2nd $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
UPDATED March 1st $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb
Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Heading to see OWCP at the wall St conference
CFN Media Exclusive Interview with OWCP CSO Dr. Yehuda Baruch
http://finance.yahoo.com/news/cfn-media-exclusive-interview-owcp-140000879.html
Marketwired MarketwiredFebruary 28, 2017
SEATTLE, WA--(Marketwired - Feb 28, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Yehuda Baruch, Chief Science Officer for OWC Pharmaceutical Research Corp. ( OTCQB : OWCP ). The interview focuses on Dr. Baruch's impressive background in cannabis research, the company's clinical trial program, and the general possibilities for cannabis as a medicine.
OWC Pharmaceuticals owns 100% of One World Cannabis Ltd., which was formed to apply pharmaceutical research protocols and disciplines to the global medical cannabis space. Dr. Yehuda Baruch spearheads the company's research efforts after serving as the head of the Israeli Ministry of Health's Medical Cannabis Program over 10 years, overseeing clinical trials, regulatory compliance, and other industry-wide issues.
OWC Pharmaceuticals is focused on the development of two delivery systems: A proprietary, cannabinoid-enriched sublingual tablet and a proprietary topical compound. Between these, the company plans to address several multi-billion dollar end markets including serious medical conditions like multiple myeloma, post-traumatic stress disorder, fibromyalgia, and psoriasis, along with hundreds of additional addressable indications down the road.
Orally disintegrating tablets
OWC Pharmaceuticals announced the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis in October of 2016. The tablet was developed to increase the bioavailability of cannabinoids and provide an optimal administration method for consistent dosing. The company plans to develop the tablet to treat conditions like multiple myeloma, post-traumatic stress disorder, and fibromyalgia.
Prior to launching the tablet, the company completed in-vitro testing of a cannabinoid-based formulation for multiple myeloma in March of 2016. Management plans to proceed with pre-clinical trials approved by the Institutional Review Board (IRB) to duplicate those results in mice before proceeding with human trials. The in-vitro testing, however, showed 100% malignant cell death in 60% of infected mice cells -- promising results.
Topical Formulation
OWC Pharmaceuticals formulated a topical cannabinoid-based cream for the treatment of psoriasis in partnership with one of Israel's largest cosmetic manufacturers -- Emilia Cosmetics Ltd. -- in March of 2016. Soon after, the company completed the Institutional Review Board (IRB) protocol for a Phase I equivalent, double-blind, randomized and placebo-controlled study and secured $300,000 in funding from U.S.-based Medmar LLC.
The company began the trial in conjunction with a major Israel-based medical center in December of 2016 to evaluate the safety and efficacy of the topical cream. Management is hopeful that the psoriasis cream will be launched in the U.S. and European markets during the second quarter of this year depending on state-to-state regulatory approvals.
Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/owcp-a-unique-pure-play-in-the-epicenter-of-cannabis-research-with-executive-interview/
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
***OWCP NEWS Feb 28th****
OWCP: A Unique Pure-Play in the Epicenter of Cannabis Research (with Executive Interview) with Dr. Baruch
http://www.cannabisfn.com/owcp-a-unique-pure-play-in-the-epicenter-of-cannabis-research-with-executive-interview/
VIDEO of Dr. Baruch
http://www.cannabisfn.com/cfnvideo/?id=DWSC3B8J
Donald Trump vs. Marijuana: Here’s who will win ?
MEDICAL MARIJUANA & OWCP
http://www.cnbc.com/2017/02/27/donald-trump-vs-marijuana-heres-who-will-win-commentary.html
OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) Analyst Review
February 27, 2017 A+A-
OWC Pharmaceutical Research Corp (OTCMKTS: OWCP), through its wholly owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
In fact, the Israeli government is one of the few countries worldwide to approve clinical studies with cannabis.
The company recently announced that it received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for treatment of psoriasis and related skin conditions.
Psoriasis cream is one of the major/critical business drivers for the company. It is in final round of efficacy testing before it hits shelves. Management confirmed that this approval is a significant milestone for the company & immediately after approval of psoriasis treatment formulation; OWCP began receiving requests for its topical psoriasis cream product from patients suffering from the condition.
OWCP further added, that after several years of extensive research, they now expect to launch psoriasis cream to the market during second quarter of 2017 or soon thereafter. Beyond psoriasis, it is also pushing multiple myeloma candidates through early stage trials, with the goal of getting the assets into clinical studies before the end of 2017. The company is scheduled to make a presentation at the Wall Street Conference on Wednesday, March 1, 2017 to discuss these developments & the future potentials in detail.
OWCP operates in Marijuana industry that has rapidly & recently turned into a multi-billion dollar massive growth market across US and Canada with many new states legalizing it. According to a recent estimates, cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sale of cannabis are set to rise to $22.8 billion in the U.S. by 2020.
There are only a handful of publicly traded companies focused on meaningful, advanced stage cannabinoid-based, pharmaceutical development. The growing popularity of this industry is seen as major inflection point for current licensed producers & researchers. In particular, existing cannabis players with sizable market cap & advanced stage product pipeline are expected to grow their business with relatively lesser competitive threats.
OWCP is one of the promising entities for cannabis investors. The company has its own IP’s, which commands significant value. Furthermore, as it move towards approval and commercialization process, the intrinsic value of the company is expected to increase significantly. With a seasoned management team, OWCP is at a critical inflection point.
In fact, supported by abovementioned reasons, company’s stock has unsurprisingly found enormous strength in the recent past. It has been powering due to the favorable impact of the company’s recent announcements and growing popularity of the industry.
Description & manufacturing set-up:
OWC Pharmaceutical, through its wholly owned subsidiary, One world Cannabis Ltd, conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. It is also developing unique delivery systems for effective delivery and dosage of medical cannabis. All its research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
One world Cannabis Ltd was set up in 2014 in Israel as a Wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP). One World offers OWCP with international access to the best research facilities and researchers in medicinal cannabis.
The state of Israel has been supportive of cannabis study and scientific research since 1960s’ in renown academic and research hospitals. The Medical Cannabis Unit under the Health Minister Office is operating in Israel since 2003.
Major Divisions of the Company:
R&D Division: All OWCP studies are following approved clinical procedures by IRB protocols conducted in Israeli hospitals facilities. Each new product targets a specific disease or medical conditions, with a particular emphasis on identifying unique formulation and efficient delivery systems to optimize the bioavailability of dosage.
Consulting Division: This division focuses on supporting and aiding organizations and states which are on the way to implement MMJ program and are looking to adopt the Israeli MMJ Methodology which includes patients’ treatments, recommended daily dosage, manufacturing standards, education programs, knowledge transfer to physicians and more.
Key Cannabis Based Products (IP owned by OWCP) – Likely to be commercialized:
Topical cream: Treatment for different skin diseases starting with tested psoriasis. Estimated market size ~8 Million Psoriasis patients US & Canada (2.5% of population).
Sublingual Soluble tablet: For conditions like, replacement of smoking & pain treatment. Estimated market size – more than 10 million potential patients in the approved MMJ states.
Strategic manufacturing, distribution & marketing Alliances:
Medmar – Based in Maryland, certain rights to manufacture, produce, publicize, promote and market OWCP’s licensed products in the United States.
Michepro – A European distribution company which signed a Joint Venture agreement, 75% (OWCP) 25% (MICHEPRO Ltd), to set up a European entity to promote, manufacture and sell OWCP products in that region.
Team & Facility:
OWCP is led by a team of experienced professionals, having substantial experience in areas of medical cannabis, clinical research, healthcare management, international business and financial markets. This knowledge, alongside their commercial experience, is likely to help OWCP’s business risk profile.
In fact, Dr. Yehuda Baruch, who is leading OWCP’s overall operations as “chief scientist officer” and regulatory affairs, is a world renowned Psychiatrist, who founded, implemented and Headed the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years.
Recent operational break-through:
It recently announced that it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for the treatment of psoriasis and related skin conditions.
Also, In October’16, OWCP completed development of a proprietary, cannabinoid-enriched sublingual tablet for administration of medical cannabis.
OWCP continues to make significant progress in R&D of cannabis-centric medical treatments, specifically with psoriasis cream, which is being readied for the U.S. and European markets. The company is focused on having products on the shelves in the MMJ states this year.
OWCP is scheduled to make a presentation in the upcoming Wall Street Conference to be held on March 1, 2017. OWCP is likely to provide an update about the Company’s progress, specifically focused on its research and products in development, and most importantly the Company’s plans for the future, sales and marketing in the US, Canada and Europe this year (2017).
Industry overview:
The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest.
Source: Investor presentation
Key Stock Influences
Some key influences that might govern future stock price performance include:
Timely initiation of U.S marketing program for Psoriasis Topical Cream during second quarter of 2017.
Meaningful and commercially viable outcomes for its ongoing research about advancement of cannabis-based treatment for multiple myeloma.
OWCP’s business risk profile is impacted by significant product concentration. There is just one thing that the company is presently relying upon i.e. “Psoriasis cream”. Therefore, OWCP’s ability to evaluate the launch of one or more studies to determine applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines – is critical for them.
OWCP is still a pre-commercial stage company and has not yet generated meaningful revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.
Also, given the fact that OWCP is burning through cash as it continues to spend in research development, it will need to access additional funding to continue operating. This is likely to lead to dilution in its present equity capital. Moreover, any sort of inability to raise fund in a timely and prudent manner, could materially & adversely affect its operations and liquidity.
Earnings Review
For quarter ended September 2016, OWCP have not generated any revenue. The company has operating expenses related to general and administrative expenses and research and development.
During three months ended September 30, 2016, it incurred a net loss of $140,794 due to general and administrative expenses of $74,898, research and development expenses of $30,363, a loss of $4,521 related to a debt settlement, interest expense of $2,055, a valuation loss on derivatives of $2,426 and expenses due to amortization of debt discount of $26,531 as compared to a net loss of $408,225 due to general and administrative expenses of $311,391 and research and development expenses of $96,834.
Operating Metrics
Its general and administrative expenses decreased by $236,493 during September 30, 2016 as compared to the same period in the prior year. This decrease of 76% is primarily the result of decreased stock-based compensation. The charge relating to stock-based compensation expense was $0 for September 30, 2016, compared to $119,199 for September 30, 2015.
Research and development expenses also decreased to $30,363 during September 30, 2016, compared to $96,834 during the same period in the prior year. The decrease by $66,471 or 69% was primarily due to decreased payments related to our collaboration agreements.
Cash Flow & Balance Sheet
OWCP has an authorized capital of 500,000,000, out of which, total outstanding shares are 139,255,474 (30 Dec 2016) & the float is 86,515,750 (31 Oct 2016)
Based upon its cash position of $90,327 as at September 30, 2016, OWCP need to raise additional capital, either through equity or debt, in order to fund its ongoing operations including research and development initiatives for the next twelve months. T
The total accumulated deficit as of September 30, 2016 and December 31, 2015 were $8,177,778 and $7,548,866, respectively.
The company recently filed form 8-K for Unregistered Sales of Equity Securities, informing that during January 9, 2017 through February 22, 2017, OWCP issued and sold equities to accredited investors.
Stock Performance
On Friday, February 24, 17, OWCP shares surged by 18.01% to $2.19 on an average volume of 4.88M shares exchanging hands. Market capitalization is $321.17 million. The current RSI is 78.82.
In the past 52 weeks, shares of OWCP have traded as low as $0.01 and as high as $3.23.
At $2.19, shares of Zeno are trading significantly above their 50-day moving average (MA) at $0.56 and above their 200-day MA at $0.18.
The present support and resistance levels for the stock are at $1.73 & $2.43 respectively.
Traders News Source Mission Statement
We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm. Please read our privacy policy and full disclaimer below.
***Receive updates and real time small cap stock profiles from Traders News Source by sending a text from your mobile phone to the number “25-827” with the word “Traders” as the message. Opt out anytime by replying “Stop”
Our group is up over 200% since January 2017 with four profiles. Stay tuned our next small cap profile will be issued via text and email soon.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
Follow $OWCP on Twitter today
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Opportunity is Everywhere if you know where to look. Get Started at E*TRADE.Advertisement
Israel has high hopes for its nascent medical marijuana sector
Nation known for its tech start-ups is tapping a new field for growth
http://www.ft.com/content/3dc71502-eeee-11e6-ba01-119a44939bb6?
High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our T&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights.
http://www.ft.stfi.re/content/3dc71502-eeee-11e6-ba01-119a44939bb6?sf=aplpxla&utm_content=buffer4b570&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer#aa
Israel has built world-class businesses in cyber security, agricultural technology and big data analysis. Now it has global ambitions in medical marijuana.
Sample the FT’s top stories for a week
You select the topic, we deliver the news.
Select topic
Enter email address Invalid emailSign up By signing up you confirm that you have read and agree to the terms and conditions, cookie policy and privacy policy.
Last week an Israeli government committee took the first step towards advancing legislation that would allow the export of medical marijuana products. Officials hope it will encourage new investment and innovation in the field and boost its agricultural sector.
There are a number of Israeli companies aiming to tap this niche but growing industry. They range from farming groups, taking advantage of Israel’s sunny climate and relaxed regulatory environment for cultivating cannabis for medical use, to companies such as Syqe Medical.
Start-up Syqe has developed a handheld inhaler, equipped with a disposable cartridge that dispenses marijuana in precise doses, down to the milligram.
Israel’s Teva Pharmaceuticals, the world’s biggest maker of generic drugs, recently signed an agreement with Syqe to distribute its product in Israel. Philip Morris, the tobacco group, invested $20m in the company in early 2016 and is studying its technology as one way to reduce the danger caused to smokers of traditional tobacco products when they combust.
Syqe’s inhaler has been in use for more than 18 months at Haifa’s Ramban hospital, where patients have been taking it for pain relief.
“We’ve developed the world’s first meter-dose system for cannabis,” says Perry Davidson, Syqe’s chief executive. The company says it has identified the “therapeutic window” between psychoactivity — the feeling of being high — and pain relief.
The medical marijuana sector is relatively new and prone to hype. It contends with concerns on how to measure doses and varying regulations around the world on how cannabis can be cultivated, tested and dispensed.
Nonetheless, it is recording some early successes in testing on a widening range of ailments.
Britain’s GW Pharma, a maker of marijuana-based medicines, has developed a cannabis-based multiple sclerosis treatment, Sativex, which is approved for use in more than 29 countries. It recently announced that its drug Epidiolex had succeeded in reducing epileptic seizures in its first significant clinical trial.
Israel’s head start in the field, like many of its other new industries, had a basis in academic research. Raphael Mechoulam, a chemist at Jerusalem’s Hebrew University, was a pioneer in isolating cannabinoids, the group of active compounds present in cannabis.
According to iCAN (Israel Cannabis), a private research and investment group that sponsors an annual conference on medical marijuana, Israel has about 50 companies operating in the field.
“We are a significant player in the cannabis space,” says Saul Kaye, iCAN’s founder and chief executive.
Syqe’s handheld inhaler dispenses marijuana in precise doses, down to the milligram © syqe medical
Israel’s rightwing government is promoting the sector, as it has other new technology industries, as a way of creating jobs and spurring investment.
The Jewish state allows producers of medical marijuana to conduct clinical trials, in contrast with the US, where testing medical cannabis on humans is forbidden.
“I think that Israel enjoys both the agricultural knowledge that is needed in order to grow marijuana, and the biotech knowledge that can improve the needed medical marijuana specifications,” says Yoav Kisch, an MP with Benjamin Netanyahu’s ruling Likud party who sponsored the bill. “This could be a very strong, good business for the Israeli agriculture industry, which has many difficulties today.”
Related article
Cannabis entrepreneurs rush to find a pot of gold
Legalisation in the US is creating commercial opportunities
Another Israeli medical company, Breath of Life Pharma, known as BOL Pharma, has developed a range of ways to deliver cannabis, including tablets that dissolve under the tongue and inhalers. This year the company is conducting or planning more than a dozen phase-two clinical trials of the drug to treat conditions ranging from Tourette’s syndrome and autism to Parkinson’s and chronic liver disease.
It is also building a factory in Jerusalem to purify and separate cannabinoids that it plans to open up to European and other companies that wish to conduct clinical trials.
“This is ‘high’ high tech,” says Tamir Gedo, BOL Pharma’s chief executive.
Drug companies say it is still too early to say whether medical marijuana will take off in earnest. One concern is that it is difficult to calibrate dosage because strength varies from batch to batch, and the use of substances such as pesticides make it difficult to produce regulated pharmaceuticals.
Kalytera, another Israeli company, is seeking to circumvent the concerns by producing a synthetic drug that it is testing on patients suffering from graft versus host disease, which afflicts some people who undergo bone marrow transplants.
“You have total control over all the aspects of the synthesis, so you know every patient will get a dose that’s understood — and a limitless supply,” says Andrew Salzman, the company’s chief executive.
Copyright The Financial Times Limited 2017. All rights reserved. You may share using our article tools. Please don't cut articles from FT.com and redistribute by email or post to the web.
Share on Twitter (opens new window)
Share on Facebook (opens new window)
Share on LinkedIn (opens new window)
7 Save
Latest on Drugs research
GSK ‘real world’ study offers model for drug trials
Big pharma bets billions on ‘silent’ liver disease
AstraZeneca boosted by positive breast cancer trial
The Big Read
Big pharma faces costly setback in cancer fight
Resistance to ‘last-resort’ antibiotic spreads in China
Read latest
GSK ‘real world’ study offers model for drug trials
Latest on Drugs research
Add to myFT
Analysis Pharmaceuticals
GSK ‘real world’ study offers model for drug trials
Pharma groups look to evidence in normal medical settings to prove value for money
Drugs research
Big pharma bets billions on ‘silent’ liver disease
Drugmakers eye potential $35bn-a-year market as cases rise due to obesity epidemic
Pharmaceuticals
AstraZeneca boosted by positive breast cancer trial
Shares rise on successful outcome for Lynparza, a drug tipped for blockbuster status
Latest in Pharmaceuticals
Add to myFT
Pharmaceuticals
Manchester mulls efficacy test for drug prices
Tie-up with drugmakers underscores city’s efforts to challenge London and Cambridge
Fast FT Jessica Dye
Merck to take $1.9bn charge on hepatitis C treatment
Fast FT Javier Espinoza
Advent offers €3.6bn for drugmaker Stada in an effort to halt bidding war
Follow the topics mentioned in this article
Pharmaceuticals Add to myFT
GW Pharmaceuticals Add to myFT
Teva Pharmaceutical Industries Add to myFT
Philip Morris International Add to myFT
Israel Add to myFT
Follow the authors of this article
John Reed Add to myFT
Take a tour of myFT
COMMENTS (7)
Sign in
+ Follow
Submit Comment
By submitting this comment I confirm that I have read and agreed to the FT Terms and Conditions. Please also see our commenting guidelines.
Newest | Oldest | Most recommended
Coase Theorem 10 days ago
Could this not be rolled into some kind o
http://www.ft.stfi.re/content/3dc71502-eeee-11e6-ba01-119a44939bb6?sf=aplpxla&utm_content=buffer4b570&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer#aa
**OWCP NEWS ***
They Know Jeff Frieland knows them well and attended then
NYC Bloomberg event and spoke about the industry and OWC
UPDATED : Wall St Conference Schedule
http://wallstconference.com/schedule/
UPDATED : Wall St Conference Sponsors
http://wallstconference.com/sponsors/
Follow $OWCP on Twitter today
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Normally I would tend to agree BUT ..
IRB Approval
new Cannabis ETF including OWCP
Sales / Marketing to Start in Q2
Clinical Trials reported to be very successful
No Dept / no convertibles
$1.6mm + in the bank
Tiny Mkt Cap vs Peers of GWPH
so I would have now disagree
Follow $OWCP on Twitter today
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
$OWCP on Twitter FOLLOW today
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* UPDATED FEB 26th $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/zqgd6nh
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
FEB 26th Follow $OWCP on Twitter
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* UPDATED FEB 26th $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/zqgd6nh
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Follow $OWCP on Twitter FEB 26th
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* UPDATED FEB 26th $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/zqgd6nh
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Follow $OWCP on Twitter today
https://twitter.com/OWCPharma
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* UPDATED FEB 26th $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/zqgd6nh
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Feller Amazing Review
Congrats all longs .. we have only just begun
Correct - and they raised $1.624 million extra in the BANK
Thanks Big Rain Coming from you
Follow $OWCP on Twitter TODAY Feb 24th
https://twitter.com/OWCPharma
**UPDATED** OWCP Corp Presentation
http://www.owcpharma.com/investors/
Downloadable PDF
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w for riends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Follow $OWCP on Twitter Feb 24th
https://twitter.com/OWCPharma
**UPDATED** OWCP Corp Presentation
http://www.owcpharma.com/investors/
Downloadable PDF
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w for riends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Dr. Baruch "the results of our efficacy studies were so encouraging that management decided it was in our interest to extend the size and scope of the study"
ZIV "We expect to the program will be in full swing by the end of the month and hope to have it completed by during the second quarter of 2017, and in the hands of patients shortly thereafter."
Follow $OWCP on Twitter Feb 24th
https://twitter.com/OWCPharma
**UPDATED** OWCP Corp Presentation
http://www.owcpharma.com/investors/
Downloadable PDF
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/hko3qzb
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w for riends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
Follow $OWCP on Twitter TODAY Feb 24th
https://twitter.com/OWCPharma
**UPDATED** OWCP Corp Presentation
http://www.owcpharma.com/investors/
Downloadable PDF
Like OWCP on Facebook
https://www.facebook.com/OWCpharma/
Follow OWCP on Instagram
https://www.instagram.com/owcpharma/
* $OWCP *OWCP 1 Page PDF Overview to Download and share
http://tinyurl.com/hko3qzb
** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months
$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/
OWCP JPEG Image to Download to your smartphone and share w for riends and family
http://tinyurl.com/z29oxku
INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true
OWCP
BREAKING TODAY WHITE HOUSE SUPPORTS MEDICAL MARIJUANA and may ENFORCE RECREATIONAL MJ